3-Amino-5,6-dimethylpyridazin | 17551-35-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-Amino-5,6-dimethylpyridazin
• 英文别名: 6-Amino-3,4-dimethyl-pyridazin；5,6-dimethyl-pyridazin-3-ylamine；5,6-Dimethylpyridazin-3-amine
• CAS: 17551-35-8
• 化学式: C₆H₉N₃
• mdl: MFCD16871484
• 分子量: 123.158
• InChiKey: FWUNCMRZTFCAAD-UHFFFAOYSA-N

物化性质

• 沸点：
  329.6±37.0 °C(Predicted)
• 密度：
  1.112±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Alzheimer's Disease Imaging Agents
  申请人：Goodman Mark M.

  公开号：US20080219922A1

  公开（公告）日：2008-09-11

  This invention provides compounds and methods of imaging amyloid deposits using radiolabeled compounds. This invention also provides a method of inhibiting the aggregation of amyloid proteins to form amyloid plaques or deposits, a method of determining a therapeutic compound's ability to inhibit aggregation of amyloid protein, and a method of delivering a therapeutic agent to amyloid deposits.

  本发明提供了使用放射性标记化合物成像淀粉样沉积物的化合物和方法。本发明还提供了一种抑制淀粉样蛋白聚集形成淀粉样斑块或沉积物的方法，一种确定治疗化合物抑制淀粉样蛋白聚集能力的方法，以及将治疗剂递送到淀粉样沉积物的方法。
• 1-(PYRIDAZIN-3-YL)-IMIDAZOLIDIN-2-ONE DERIVATIVES AS HERBICIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：US20160262395A1

  公开（公告）日：2016-09-15

  The invention relates to pyrrolone compounds of the formula (I) wherein R 1 , R 2 , R 3 , R b , R c and R d are as defined in the specification. Furthermore, the present invention relates to processes and intermediates for making compounds of formula (I), to herbicidal compositions comprising these compounds and to methods of using these compounds to control plant growth.

  本发明涉及式(I)的吡咯烷化合物，其中R1，R2，R3，Rb，Rc和Rd如规范中所定义。此外，本发明涉及制备式(I)化合物的过程和中间体，包括这些化合物的除草剂组合物以及使用这些化合物控制植物生长的方法。
• HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE
  申请人：Amgen Inc.

  公开号：US20210171529A1

  公开（公告）日：2021-06-10

  The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5D”). The compounds have a general Formula 1: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
• US9723840B2
  申请人：——

  公开号：US9723840B2

  公开（公告）日：2017-08-08